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Abstract
This study aimed to determine whether brain-derived neurotrophic factor
(BDNF) variants are related to premorbid educational attainment, progression of
cognitive and functional decline, and associated neuropsychiatric symptoms in patients
with Alzheimer’s disease (AD). A sample of n = 341 AD subjects was genotyped for the
BDNF polymorphisms val66met, C270T, and G-712A. Subjects received tests of
cognition and daily function at baseline and at multiple subsequent time points during
their participation in a variety of research protocols. Cognition was measured by the
Mini-Mental State Examination (MMSE) and Alzheimer’s Disease Assessment Scale
(ADAS-Cog). Functional performance was assessed using the Instrumental Activities of
Daily Living questionnaire (IADL) as well as the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living inventory (ADCS-ADL). Subjects were also
characterized for the frequency and severity of neuropsychiatric symptoms using the
Neuropsychiatric Inventory (NPI). There was a significant effect of val66met genotype
on educational attainment (F = 7.42, df = 2, 329, P = .00070), with met homozygotes
having significantly fewer years of education than both the val/met and val/val groups.
No association was observed between any BDNF polymorphism and measures of
cognitive or functional decline. The C270T-T allele was associated with a higher
prevalence of neuropsychiatric symptoms (Z = -2.11, N = 241, p = .035) and specifically
with the presence of hallucinations (OR = 3.25, 95% CI = [1.22-8.62], p = .018). In
summary, the val66met polymorphism appears to be associated with lower premorbid
educational attainment in AD patients. The C270T-T allele demonstrated association with
total neuropsychiatric symptoms and specifically hallucinations. BDNF genotypes in this
sample do not confer a more rapid rate of cognitive or functional decline.
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1
Introduction
Neurotrophins function in neuronal development and maintenance (1, 2).
Brain-derived neurotrophic factor (BDNF) is a neurotrophin involved in
modulation of episodic memory that occurs in the hippocampus (3-6). It is
believed that disruption of BDNF may lead to learning and memory deficits (4, 613). Consequently, the BDNF gene is of interest to researchers investigating
neurodegenerative disease and cognitive impairment.
Decreased levels of BDNF mRNA have been observed in brains of
patients with Alzheimer’s disease (AD) in the parietal cortex (14) and
hippocampus (15). Evidence also suggests that serum levels of BDNF reflect
severity of AD, correlating with Mini-Mental State Examination (MMSE) scores
(16). Measurement of serum BDNF levels in patients with vascular dementia does
not demonstrate the decrease observed in AD (17). Donepezil, an
acetylcholinesterase inhibitor with demonstrated cognitive and functional benefits
for patients with AD, has been found to increase BDNF serum concentrations in
patients to the level of healthy controls (18). The specific molecular mechanism
linking acetylcholinesterase and BDNF, however, has not been elucidated.
Because of the increasing evidence that BDNF may play a role in AD,
polymorphisms of this gene are being studied to understand better the
contribution of genetics to this complex condition.
Geneticists have recently identified several polymorphisms of BDNF:
C270T, val66met (G196A), and G-712A. Previous research into the role of these
polymorphisms in the pathogenesis of AD has been conflicting. The T allele of
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the C270T polymorphism has been identified in several studies to be associated
with AD (19-22) as well as early-onset AD in patients lacking the apolipoprotein
E (ApoE) ε4 allele, an established risk factor for AD (23). However, other studies
found no association (24-29).
Although the majority of studies examining val66met have found no
association with AD (20, 25, 27-36), at least two studies have suggested higher
frequencies of the val allele among patients with AD (19, 37). Additionally,
val66met has been associated with memory performance, in which patients
carrying the met allele demonstrate poorer episodic memory (38-40).
The G-712A allele was recently identified by our group (29) and was not
found to have an association with AD.
Regardless of whether BDNF polymorphisms play a direct role in
predisposing patients to develop AD, the role of this gene in modulating learning
and memory suggests that it may influence the rate of progression and associated
symptoms of this disease. The clinical presentation of AD is heterogeneous,
involving not only memory deficits but also an array of neuropsychiatric
comorbidities that may or may not present in a particular patient. Several
investigators have suggested that distinct phenotypes may be evident in cases
where AD is comorbid with psychosis (41-44) or with major depressive disorder
(45-47), as compared to AD cases in which those conditions are absent.
BDNF polymorphisms have already been investigated with respect to
some of these neuropsychiatric conditions in patients without AD. Extensive
literature exists evaluating the role of BDNF gene variants in schizophrenia, for
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which the clinical presentation is largely characterized by psychotic symptoms of
hallucinations and delusions. It has been reported that the val allele is associated
with schizophrenia (48), although the met/met genotype has a significantly lower
age of schizophrenia onset than val/val (49). There is also evidence for
preferential inheritance of the val allele among patients with psychosis and
schizophrenia spectrum disorder (50). The C270T-T allele has been documented
in higher frequency among patients with schizophrenia than healthy controls (51,
52). However, multiple studies suggest that BDNF polymorphisms have no
association with schizophrenia (29, 53-55). Other variables have been studied in
patient populations with schizophrenia to evaluate the effect of BDNF gene
variants, and it has been observed that val homozygotes have higher scores of
logical memory than met/val or met/met counterparts (56). Among patients with
schizophrenia, those who were classified as catatonic had lower average serum
BDNF than those who were paranoid or residual (57).
The association between BDNF and major depressive disorder (MDD) has
also been studied. It has been reported that in a Chinese population there is an
excess of the met allele of val66met among geriatric patients with depression
(58). Additionally, low plasma levels of BDNF have been associated with MDD
(59) and suicidal behavior in MDD (60). Concordantly, mouse models suggest
that increased BDNF signaling has an antidepressant-like effect (61), and there is
an increase in BDNF immunoreactivity in post-mortem tissue of patients treated
with antidepressant drugs (62). A recent investigation of depression in AD found
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an association between the met allele and depressive symptoms in these patients
(63).
Research into the association of BDNF with other neuropsychiatric
conditions has included studies of anxiety, panic disorder, affective disorders,
post-traumatic stress disorder (PTSD), substance dependence, and general
neurocognitive dysfunction. It has been demonstrated that val homozygotes have
higher levels of anxiety than other val66met genotypes (64), and patients with
panic disorder who have lower levels of serum BDNF have poorer response to
cognitive behavioral therapy (65). No associations were observed between G712A, C270T, or val66met polymorphisms and affective disorder or PTSD,
although a slight association was discovered between G-712A and substance
dependence (29). Additionally, among patients with systemic lupus
erythematosus, the met allele of val66met was associated with better cognitive
functioning in psychomotor and motor domains (66).

Statement of Purpose, Specific Hypothesis, and Specific Aims
Patients with AD present with a vast array of neuropsychiatric
comorbidities in addition to cognitive and functional impairment, with little
evidence currently in the literature to help predict why there is such variability in
these phenotypes among the AD patient population. Having observed discrepant
reports in the literature regarding the role of BDNF in AD and separately in other
neuropsychiatric conditions, the purpose of this investigation is to evaluate the
effect of BDNF polymorphisms on cognitive, functional, and behavioral
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symptoms in AD. We hypothesized that val66met met homozygotes would have
an earlier age of onset and lower educational attainment than other genotypes
based on the multiple studies suggesting the met allele is associated with poorer
memory performance(38-40). We also hypothesized that psychotic symptoms,
including hallucinations and delusions, would be more highly associated with the
C270T-T allele based on studies in which this allele was more common among
patients with schizophrenia (51, 52). Our study was conducted with the aim to
provide insight into the specific role of BDNF in AD, and more broadly to
understand the genetic basis of particular phenotypes of this disease.

Method
Subjects
The study sample comprised 341 patients with probable AD (67) who
enrolled in a study of the genetics of AD and were initially evaluated in the Yale
Alzheimer’s Disease Research Unit (ADRU). Most of these patients participated
in a variety of other research protocols permitting the accumulation of
longitudinal cognitive and functional data. Nineteen of these patients have
subsequently died and had autopsy confirming definite AD (68). The
demographics and clinical characteristics of patients are displayed in Table 1. The
racial composition of the sample was: European-American (n=343; 97.7%),
African-American (n=6; 1.7%), and Hispanic (n=2; 0.57%).
All patients underwent a comprehensive evaluation by a research
physician and ancillary staff, including cognitive assessment, medical history,
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physical and neurological examinations, serum chemistries, thyroid function
studies, complete blood count, B12, folate, VDRL, urinalysis, electrocardiogram,
and brain MRI or CT scan. Subjects were excluded for any neurological or
medical disorder (other than AD) that could produce cognitive deterioration or for
significant psychiatric illness, alcohol, or substance abuse. Research protocols in
which subjects participated following their initial evaluation included
investigational therapeutic trials, neuroimaging studies, and neuropsychological
studies. Some investigational and clinically prescribed AD treatments received by
subjects—in particular acetylcholinesterase inhibitors, high-dose vitamin E (≥ 400
IU daily), and psychotropic drugs—may potentially have impacted behavioral
variables analyzed in this study. These treatments were assumed to be
independently distributed with regard to BDNF genotype; however, this
assumption was also tested statistically (see below).
Family history of AD was assessed using the Alzheimer Dementia Risk
Questionnaire (69) and the Dementia Questionnaire (70) through extensive
caregiver interview. Family history was considered positive if at least one firstdegree relative met criteria for primary degenerative dementia. Caregiver
interview was also used in conjunction with review of medical records to
approximate the onset date of AD, estimated to the month of which the earliest
definite symptom was noticed. All subjects (or their responsible next of kin)
provided written informed consent and were studied under a protocol approved by
the Yale Human Investigation Committee.
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Evaluation
Subjects were evaluated using a number of cognitive, functional, and
neuropsychiatric tests and rating scales at the time of initial presentation (see
Tables 2 and 4). Several of these measures were repeated longitudinally, at
varying frequencies, depending on the different requirements of the research
protocols in which subjects subsequently participated. Many subjects enrolled in
multiple studies spanning several years.

Cognitive Performance. The cognitive performance of subjects was
measured using the Mini-Mental State Examination (MMSE) (71) and the
cognitive subscale of the Alzheimer’s Disease Assessment Scale (ADAS-Cog)
(72). The MMSE evaluates cognition on a scale of 0 (maximal impairment) to 30
(no impairment) through tests of memory, orientation, and praxis. The ADASCog is a neuropsychological battery that targets specific domains of cognition
including memory, orientation, praxis, and language. The ADAS-Cog is much
more sensitive than other testing, with a range of scores from 0 to 70 for which
higher scores indicate greater cognitive impairment. This battery is frequently
employed to measure efficacy of treatment in drug trials and has been shown to be
a reliable predictor of cognitive decline in patients with probable AD (73, 74). Of
these measures, the medical student author performed approximately 150 MMSE
evaluations and 40 ADAS-Cog evaluations. The remainder was completed by
ancillary staff at the ADRU.
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Functional Performance. The functional capacity of subjects in activities
of daily living was assessed through caregiver interview using both the
Instrumental Activities of Daily Living (IADL) questionnaire (75) and the
Alzheimer’s Disease Cooperative Study-Activities of Daily Living inventory
(ADCS-ADL) (76). The IADL was performed only once at baseline (and
therefore included in retrospective but not prospective analyses) and evaluated
everyday functioning along eight domains: using the telephone, shopping, food
preparation, housekeeping, laundry, transportation, handling medications, and
finances (75). A score of 1 for a given domain indicated no impairment and 0
indicated inability to complete that task. Since not all domains were valid for all
subjects (e.g. men who never did laundry before AD onset), the IADL score was
calculated as the sum of individual activity scores divided by the total possible
valid points for that subject. The ADCS-ADL provides a comprehensive
assessment of ADL performance across 28 functional domains and is scored from
0 (maximal impairment) to 78 (no impairment) (76). Use of these inventories
previously was described by our group in a study of ApoE genotype and
functional decline (77). Of these evaluations, approximately 35 IADLs were
completed by the medical student author. The remainder of these exams was
performed routinely by research staff at the ADRU.

Neuropsychiatric symptoms. All subjects were evaluated for behavioral
and psychological symptoms using the Neuropsychiatric Inventory (NPI), a
structured interview that assessed the frequency and severity of these symptoms
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(78). Using scripted questions, a caregiver was asked whether the patient’s
behavior had changed after the onset of dementia and whether the altered
behavior had been present during the month preceding the evaluation. This format
therefore distinguished between psychiatric symptoms that may have been present
before the onset of dementia, and those that emerged during the disease process.
The NPI assessed the following behavioral domains: delusions, hallucinations,
agitation, depression, anxiety, elation, apathy, disinhibition, irritability, aberrant
motor behavior, sleep disturbances and eating disturbances. Specific follow-up
questions were used to confirm the presence of symptoms that were reported
positive. For each domain in which symptoms were confirmed, the caregiver was
asked to score the frequency with which symptoms occurred as: occasionally (1),
often (2), frequently (3) or very frequently (4). The caregiver was asked also to
score the severity of disturbances as: mild (1), moderate (2) or marked (3).
Domains absent of disturbances were scored as 0. The product of the frequency
and severity score was determined for each positive item (range=1-12), and the
sum of all item scores yielded the total NPI score. Possible scores ranged from 0
(no behavioral disturbances) to 144 (all behavioral disturbances maximally
present). Use of the NPI was described previously by our group in a study of
ApoE genotype association with psychotic symptoms (79). Of these NPI
evaluations, approximately 35 were completed by the medical student author.
The remainder was performed routinely by research staff at the ADRU.
Of the cognitive, functional, and neuropsychiatric measures, the MMSE
was performed on the entire sample (N = 341), whereas all other measures were
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available for only certain subsets of the subject population (as detailed in Tables 2
and 4). All subject data were obtained by trained raters who were unaware of the
subjects’ BDNF genotypes.

Determination of BDNF genotypes
BDNF genotype determination was performed at the VA Connecticut
Healthcare System, West Haven, CT, by Dr. Joel Gelernter and colleagues. As
previously described by our group (29), BDNF sequence information was
obtained through the public "GoldenPath" database (http://genome.ucsc.edu).
Fifteen pairs of primers were designed to amplify part of the 5’ region, the
noncoding exon I, and the only coding exon V of the BDNF gene (29). Amplicons
derived from 16-48 DNA samples of the above patients with various diagnoses
and healthy controls were scanned using denaturing high performance liquid
chromatography (dHPLC). A dHPLC mutation screen of the BDNF gene was
carried out by using the “Wave” DNA Fragment Analysis System (Transgenomic,
USA). Five-15 µl of the polymerase chain reaction (PCR) mixture was loaded on
a “DNASep” cartridge using a linear acetonitrile gradient in a triethylamine buffer
at a constant flow rate of 0.9 ml/min. The gradient was created by mixing the
eluents A (0.1 M triethylamine) and B (0.1 M triethylamine and 25% Acetonitrile)
at concentrations determined by the Transgenomic “Wavemaker” software.
Samples that showed mobility shifts were sequenced using cycling sequencing
and fluorescently labeled dideoxynucleotides on an ABI 3100 Genetic Analyzer
(Applied Biosystems). A newly identified SNP, G-712A (29), and two previously
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reported SNPs, C270T (21) and Val66Met (80), were genotyped in patients with
AD by PCR and restriction fragment length polymorphism (PCR-RFLP) analysis.
Primer pairs and PCR conditions for genotyping the three BDNF SNPs have been
previously summarized (29).

Statistical Analysis
Analyses of the val66met polymorphism involved three-group
comparisons (val/val, val/met, met/met). However, the C270T and G-712A
polymorphisms were studied using two-group comparisons between carriers and
non-carriers of the less frequent allele, given the scarcity of homozygotes for the
C270T T-allele (n = 3) and the G-712A A-allele (n = 2). Subject characteristics
(including demographics, disease characteristics, and concomitant therapies) were
compared across gene dose groups using Student’s t-test or analysis of variance
(ANOVA) for continuous variables or chi-square analysis for dichotomous
variables.
The effect of each BDNF polymorphism on the rate of AD progression
was analyzed using both retrospective and prospective techniques similar to those
employed in our previous study of ApoE ε4 (77). The retrospective analyses
examined cross-sectional cognitive (MMSE, ADAS-Cog) and functional (IADL,
ADCS-ADL) data obtained at each subject’s initial visit, while controlling for the
duration of symptoms by analysis of covariance (ANCOVA). Although disease
duration was the essential covariate in all retrospective analyses, age, sex, and
educational attainment were also included as covariates in the ANCOVA models.

12
Prospective analyses of disease progression were also conducted for the
MMSE, ADAS-Cog, and ADCS-ADL for all subjects who had at least two
observations spanning at least six months of research participation. For these
analyses, an annualized rate of change in performance on each scale was
calculated by least-squares regression, using all available measurements for each
subject. Rates of change were compared across BDNF genotype groups by
ANCOVA, controlling for age, sex, and education.

Behavioral Outcomes. We derived an NPI-Psychosis score for each
subject by summing the domain scores for the delusions and hallucinations
sections of the full NPI. Subjects with an NPI-Psychosis score of 1 or greater
were coded positively for the AD+Psychosis phenotype. These criteria reflect our
conception of an AD “phenotype” as an identifiable condition in which psychotic
disturbances occur with substantial frequency and/or severity. Each BDNF
genotype was analyzed as a potential predictor of the AD+Psychosis phenotype
using separate logistic regression models. In the AD+Psychosis model, MMSE
score and ApoE ε4 genotype were included as covariates because our previous
study found them significant, independent predictors of this phenotype (79).
An exploratory analysis of the association between BDNF and other
behavioral disturbances in AD was conducted, using the rest of the data from the
NPI. It was observed that the distribution of total NPI scores did not satisfy the
assumption of normality because of a “floor effect” – many subjects scored zero.
Nonparametric analyses (Mann-Whitney U or Kruskal-Wallis H) were employed

13
to determine if specific genotype groups differed in total NPI score. Logistic
regression analyses were performed to explore whether BDNF genotype predicted
zero vs. nonzero domain scores on each item of the NPI (e.g. irritability, anxiety).
The literature does not provide a clear indication of the appropriate covariates for
each item of the NPI. Covariates chosen included sex, age at time of testing,
MMSE score, and education level. This analysis makes no assumptions about the
nature of AD phenotypes; rather, it explores whether BDNF genotype is related at
all to the appearance of specific behavioral disturbances within an AD population.

Results
The genotypic distribution of these three SNPs—val66met, C270T, and G712A—was consistent with Hardy-Weinberg equilibrium expectations (data not
shown).

Demographics
Table 1 presents the demographic and clinical characteristics of the entire
sample, as well as each genotype group. Within the AD sample, val66met
genotypes were available for n = 332 subjects; C270T genotypes for n = 332
subjects; and G-712A genotypes for n = 310 subjects. The two planned
comparisons of educational attainment and age of onset among val66met groups
were analyzed. There was a significant effect of val66met genotype on
educational attainment (F = 7.42; df = 2, 329; P = .00070) (See Figure 1). Posthoc Tukey test revealed that the met/met homozygote group had significantly
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lower education than both the val/met heterozygotes (P = .00062) and the val/val
homozygotes (P = .0068). However, the val/met heterozygote and val/val
homozygote groups did not differ from each other (P = .13). There was no
significant effect of either C270T or G-712A genotype on educational attainment.
There was no significant effect of any of the three polymorphisms with regard to
age of disease onset.
Few significant demographic differences were observed across genotype
groups. In our sample, carriers of the A712 allele were disproportionately female
(χ2 = 4.57, df = 1, P = .032). Treatment history for acetylcholinesterase
inhibitors, anti-psychotics, antidepressants and high-dose vitamin E was
distributed independently with respect to genotype. The only exception was that
our sample of met/met was significantly more likely than val/val or val/met
groups to have been taking acetylcholinesterase inhibitors at the time of study
assessment (χ2 = 6.21, df = 1, P = 0.045). Apart from these observations, all
genotype groups were well matched for demographic and disease characteristics.

Retrospective Analysis of Cognitive and Functional Progression
Table 2 presents a summary of the retrospective analyses of cognitive and
functional progression in AD patients. It specifically contains the baseline
cognitive and functional data according to BDNF genotypes.

Val66met
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MMSE performance was analyzed in the overall sample of n = 332
subjects. Gene dose groups did not differ significantly in MMSE performance (F
= 0.65; df = 2, 325; P = .52), controlling for disease duration, age, sex, and
education.
ADAS-Cog performance was analyzed in a sub-sample of n = 274
subjects. The demographic profile of this sub-sample and all others analyzed
below did not differ from that of the overall sample characterized in Table 1.
Gene dose groups did not differ significantly in ADAS-Cog performance (F =
0.75; df = 2, 267; P = .47), controlling for disease duration, age, sex, and
education.
IADL performance was analyzed in a sub-sample of n = 320 subjects.
Gene dose groups did not differ significantly in IADL performance (F = 0.01; df
= 2, 313; P = .99), controlling for disease duration, age, sex, and education.
ADCS-ADL performance was analyzed in a sub-sample of n = 165
subjects. Gene dose groups did not differ significantly in ADCS-ADL
performance (F = 0.84; df = 2, 158; P = .43), controlling for disease duration, age,
sex, and education.

C270T
MMSE performance was analyzed in the overall sample of n = 332
subjects. Gene dose groups did not differ significantly in MMSE performance (F
= 0.01; df = 1, 326; P = .93), controlling for disease duration, age, sex, and
education.
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ADAS-Cog performance was analyzed in a sub-sample of n = 275
subjects. The demographic profile of this sub-sample and all others analyzed
below did not differ from that of the overall sample characterized in Table 1.
Gene dose groups did not differ significantly in ADAS-Cog performance (F =
0.04; df = 1, 269; P = .83), controlling for disease duration, age, sex, and
education.
IADL performance was analyzed in a sub-sample of n = 320 subjects.
Gene dose groups did not differ significantly in IADL performance (F = 0.60; df
= 1, 314; P = .44), controlling for disease duration, age, sex, and education.
ADCS-ADL performance was analyzed in a sub-sample of n = 165
subjects. Gene dose groups did not differ significantly in ADCS-ADL
performance (F = 0.40; df = 1, 159; P = .53), controlling for disease duration, age,
sex, and education.

G-712A
MMSE performance was analyzed in the overall sample of N = 310
subjects. Gene dose groups did not differ significantly in MMSE performance (F
= 0.12; df = 1, 304; P = .73), controlling for disease duration, age, sex, and
education.
ADAS-Cog performance was analyzed in a sub-sample of n = 261
subjects. The demographic profile of this sub-sample and all others analyzed
below did not differ from that of the overall sample characterized in Table 1.
Gene dose groups did not differ significantly in ADAS-Cog performance (F =
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0.02; df = 1, 255; P = .90), controlling for disease duration, age, sex, and
education.
IADL performance was analyzed in a sub-sample of n = 299 subjects.
Gene dose groups did not differ significantly in IADL performance (F = 0.78; df
= 1, 293; P = .38), controlling for disease duration, age, sex, and education.
ADCS-ADL performance was analyzed in a sub-sample of n = 154
subjects. Gene dose groups did not differ significantly in ADCS-ADL
performance (F = 1.15; df = 1, 148; P = .29), controlling for disease duration, age,
sex, and education.

Prospective Analysis of Cognitive and Functional Progression
Table 3 presents a summary of the prospective analyses of cognitive and
functional progression in AD patients. It specifically contains the annualized rates
of change for cognitive and functional measures according to BDNF genotypes.

Val66met
Annualized rate of change in MMSE performance was analyzed in a subsample of n = 215 subjects. Subjects received an average of 6.7 assessments
(range = 3-18) spanning 1.8 years of follow-up (range = 0.5-6.4). The rate of
MMSE change did not differ significantly across gene dose groups (F = .00; df =
2, 209; P = 1.00), controlling for age, sex, and education.
Annualized rate of change in ADAS-Cog performance was analyzed in a
sub-sample of n = 179 subjects. Subjects received an average of 9.4 assessments
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(range = 3-25) spanning 1.6 years of follow-up (range = 0.5-5.8). The rate of
ADAS-Cog change did not differ significantly across gene dose groups (F = .04;
df = 2, 173; P = .97), controlling for age, sex, and education.
Annualized rate of change in ADCS-ADL performance was analyzed in a
sub-sample of n = 156 subjects. Subjects received an average of 7.1 assessments
(range = 3-18) spanning 1.4 years of follow-up (range = 0.5-4.9). The rate of
ADCS-ADL change did not differ significantly across gene dose groups (F = .41;
df = 2, 150; P = .67), controlling for age, sex, and education.

C270T
Annualized rate of change in MMSE performance was analyzed in a subsample of n = 213 subjects. Subjects received an average of 6.7 assessments
(range = 3-18) spanning 1.8 years of follow-up (range = 0.5-6.4). The rate of
MMSE change did not differ significantly across gene dose groups (F = .69; df =
1, 208; P = .41), controlling for age, sex, and education.
Annualized rate of change in ADAS-Cog performance was analyzed in a
sub-sample of n = 179 subjects. Subjects received an average of 9.4 assessments
(range = 3-25) spanning 1.6 years of follow-up (range = 0.5-5.8). The rate of
ADAS-Cog change did not differ significantly across gene dose groups (F = 2.47;
df = 1, 174; P = .12), controlling for age, sex, and education.
Annualized rate of change in ADCS-ADL performance was analyzed in a
sub-sample of n = 154 subjects. Subjects received an average of 7.1 assessments
(range = 3-18) spanning 1.4 years of follow-up (range = 0.5-4.9). The rate of
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ADCS-ADL change did not differ significantly across gene dose groups (F = .01;
df = 1, 149; P = .94), controlling for age, sex, and education.

G-712A
Annualized rate of change in MMSE performance was analyzed in a subsample of n = 198 subjects. Subjects received an average of 6.7 assessments
(range = 3-18) spanning 1.8 years of follow-up (range = 0.5-6.4). The rate of
MMSE change did not differ significantly across gene dose groups (F = 1.33; df =
1, 193; P = .25), controlling for age, sex, and education.
Annualized rate of change in ADAS-Cog performance was analyzed in a
sub-sample of n = 171 subjects. Subjects received an average of 9.4 assessments
(range = 3-25) spanning 1.6 years of follow-up (range = 0.5-5.8). The rate of
ADAS-Cog change did not differ significantly across gene dose groups (F = 3.24;
df = 1, 166; P = .07), controlling for age, sex, and education.
Annualized rate of change in ADCS-ADL performance was analyzed in a
sub-sample of n = 145 subjects. Subjects received an average of 7.1 assessments
(range = 3-18) spanning 1.4 years of follow-up (range = 0.5-4.9). The rate of
ADCS-ADL change did not differ significantly across gene dose groups (F =
0.83; df = 1, 140; P = .40), controlling for age, sex, and education.

Analysis of Behavioral Symptoms
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Table 4 summarizes the behavioral outcomes measured by the NPI,
including percentage of subjects with each neuropsychiatric symptom as well as
odds ratios for these symptoms by genotype.
NPI data were available for n = 248 subjects in our AD sample. Of these,
val66met and C270T genotypes were available for n = 241 subjects, and G-712A
genotypes were available for n = 222. No significant differences in Total NPI
score across genotype groups were found by a Kruskal-Wallis H test for val66met
(χ2 = 1.61, df = 2, N = 241, p = .45). Carriers of the C270T-T allele had a higher
mean rank for Total NPI score as revealed by Mann-Whitney U test, indicating a
greater prevalence of behavioral disturbances in that group (Z = -2.11, N = 241, p
= .035). G-712A genotype groups did not differ in Total NPI score (Z = -1.66, N =
222, p = .098).
Our selection criterion identified n = 86 subjects with the Psychosis ≥1
phenotype (n = 164 subjects without). This phenotype was not associated with
genotype for val66met (OR = 2.94, 95% CI = [0.58, 15.04]), C270T (OR = 2.23,
95% CI = [0.88-5.63]), or G-712A (OR = 1.89, 95% CI = [0.71-4.97]).
In our exploratory logistic regression models, neither val66met nor G712A genotype was associated with the appearance of behavioral disturbances on
any NPI domain. The C270T-T allele was associated with the presence of
hallucinations (OR = 3.25, 95% CI = [1.22-8.62], p = .018) but not with
disturbances in any other specific NPI domain.
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Discussion
This is the first study to evaluate the role of three BDNF polymorphisms
with respect to cognitive and functional progression and behavioral symptoms in
AD. Analysis of val66met found met homozygotes to have significantly lower
educational attainment relative to val/met and val/val genotypes. Although
retrospective and prospective analyses of cognitive and functional progression
revealed no association with the val66met, C270T, or G-712A polymorphisms,
analysis of behavioral symptoms demonstrated an association between the
C270T-T allele and presence of hallucinations as well as increased total NPI
score.
The most striking finding of this study was the highly significant effect of
val66met genotype on educational attainment, as we hypothesized, demonstrating
an association between met homozygosity and fewer years of education. Limited
research has been conducted examining the relationship between educational
attainment and BDNF genotype. Chuu et al. demonstrated within an AD
population a trend towards lower educational attainment among met homozygotes
(13.2 years vs. 14.0 years for val/val and 14.3 years for val/met genotypes),
consistent with our finding, although this difference was not statistically
significant (81). This trend was also true of a recent study by Borroni et al. in
which met homozygotes had 0.99 fewer years of education than val homozygotes
and 0.91 fewer years than heterozygotes (63). Taylor et al. observed no difference
in education level between val homozygotes and met carriers among patients with
depression and healthy controls; met homozygotes were not distinguished from
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heterozygotes in this study due to small sample size (82). This is consistent with
our finding inasmuch as our group demonstrated a significant difference only
between met homozygotes and the other genotypes. Egan et al. demonstrated no
significant effect of val66met on educational attainment among patients with
schizophrenia, their siblings, or healthy controls; however, met homozygotes
trended toward more years of education—17.7 years—when compared with val
homozygotes (16.2 years) and heterozygotes (16.7 years) (38).
The discrepancies among these studies may be explained in part by the
presence of AD among patients in our sample and in the Chuu et al. and Borroni
et al. studies. Low level of educational attainment has been described as a risk
factor for AD (83-90). It has been demonstrated that patients with higher
educational attainment perform better on neuropsychological testing and are less
likely to meet criteria for dementia when at the same neuropathological stage of
AD as less-educated counterparts (91, 92). A systematic review of studies of
“cognitive reserve” and risk of dementia found a 46% decreased risk of AD
among patients with a high brain reserve (that is, those with “complex mental
activity across the lifespan”) (93). Whether education provides a cognitive reserve
to protect individuals from developing AD, or more highly educated people
perform better on the neuropsychological testing employed to diagnose dementia,
is a point of debate (90). It is possible that the effect of genotype on educational
attainment observed in our study might be a consequence of the sample of AD
patients, as they may have had a lower baseline cognitive reserve than a sample of
non-AD counterparts.
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Although the relationship of BDNF polymorphisms and educational
attainment has not been studied in detail, researchers have examined the
association of BDNF polymorphisms with memory performance. Several studies
suggest that met carriers exhibit impaired episodic memory relative to val
homozygotes (38-40). A second interpretation of our finding might be that
patients who are met homozygotes (or, taking results of prior studies into
consideration, met carriers, as our study may not have been sensitive enough to
detect significant differences in educational attainment among heterozygotes)
have impaired memory ability, consequently may have more difficulty with
academic performance, and ultimately may have lower overall educational
attainment. In conjunction with the cognitive reserve hypothesis, it would follow
that if lower educational attainment is associated with risk of AD, one would
expect met carriers to demonstrate higher rates of AD than val homozygotes.
However, the vast majority of studies examining risk of AD with the val66met
polymorphism demonstrate no association (20, 25-28, 30-34), or association of
the val allele with AD (19, 37). Additionally, one would expect that met carriers
would have a lower age of onset, as we hypothesized, because they lack the
protective factor of cognitive reserve. However, our study suggests that there is
no association, and this is in agreement with other studies (30, 94).
The other significant demographic findings of this study—that met
homozygotes were more likely to be taking acetylcholinesterase inhibitors at the
time of assessment, and that significantly more women carried the A712 allele—
are more challenging to interpret. The significantly higher use of
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acetylcholinesterase inhibitors may be related to the findings that the met allele
predisposes to impaired episodic memory relative to other genotype groups (3840): a drop in memory performance from a lower baseline may incite these
patients to seek medication at an earlier stage than counterparts who declined
from a higher baseline and therefore remain more functional. Because so little is
known about the G-712A polymorphism or its effects physiologically, reasons for
women to carry the A712 allele are unclear and more research should be
conducted to determine whether this relationship holds in non-AD samples.
The finding that val66met, C270T, and G-712A polymorphisms are
unrelated to rate of cognitive decline in AD is consistent with a previous study in
which val66met was found to have no association with rate of change of MMSE
score (81). While Chuu et al. determined rate of change by sequential MMSE
scores, our study determined rate of change both this way and retrospectively,
using approximate onset date of AD to estimate disease duration at time of
testing. Cognitive decline was additionally measured by ADAS-Cog scores,
following methods to evaluate rate of cognitive decline previously employed by
our group (77) and others (95). To our knowledge, this is the only study to offer
both retrospective and prospective analyses of cognitive decline as well as to
examine ADAS-Cog scores in relation to these BDNF polymorphisms. Of note,
this methodology follows our previous study of ApoE, in which no relationship
was established between rate of cognitive decline and ApoE, corroborating data
from several other groups (96-109), but in contrast to data from three studies
suggesting ε4 accelerates rate of cognitive decline (95, 110, 111). It should be
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clarified that no association between ApoE and BDNF genotypes has been
established (20, 21, 25, 31, 33-35, 37), although it has been suggested that the
C270T-T allele is more common among individuals lacking ε4 (19), and the risk
of AD conferred by the C270T-T allele is stronger in patients who do not carry ε4
(23).
No studies were identified in the literature examining rate of functional
decline with respect to BDNF polymorphisms. Borroni et al. demonstrated no
association of val66met genotype with cross-sectional IADL score for patients
with AD, but this single measurement did not estimate rate of decline (63).
The association of the C270T-T allele and increased total NPI score is
difficult to interpret given the variety of psychiatric domains evaluated by this
scale. We hypothesized that psychotic symptoms would be more prevalent in this
genotype group given previous association studies with the polymorphism and
schizophrenia. However, only “hallucinations” showed a significant association
with the allele; no association with “psychosis” was established when
hallucinations and delusions were considered together. This was of interest to our
group given our previous finding of an association between ApoE ε4 and
psychotic symptoms in AD, particularly from an association with delusions (79).
The differences between the BDNF and ApoE studies again reinforce that these
are distinct genotypes whose effects are accrued independently from one another.
Several studies in the literature have examined the relationship between BDNF
polymorphisms and schizophrenia. Consistent with our finding, the C270T-T
allele has been documented in higher frequency among patients with
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schizophrenia than healthy controls (51, 52). Our finding that hallucinations were
not associated with val66met genotype is consistent with the findings of Borroni
et al., who found no association of psychotic symptoms in AD patients
specifically with this allele (63). Although psychotic symptoms were not
associated with val66met in our study, it has been reported that the val allele is
associated with schizophrenia (48). There is also evidence for preferential
inheritance of the val allele among patients with psychosis and schizophrenia
spectrum disorder (50). Multiple studies, however, including one from our own
group, suggest that BDNF polymorphisms have no association with schizophrenia
(29, 53-55). Conflicting data among these studies emphasizes the need for further
examination of the role of BDNF polymorphisms among patients with psychotic
symptoms, both those with AD and those with schizophrenia.
Our study did not find an association of val66met genotype with total NPI
score or sub-categories of the NPI. This disputes the recent investigation by
Borroni et al. that demonstrated a significant association between the met allele
and increased total NPI score as well as NPI depression and apathy scores (63).
One possibility for this discrepancy is that the Borroni study examined a cohort of
depressed AD patients that may have contributed a disproportionately large
number of patients with neuropsychiatric disturbances to the sample. Our sample
included 83 patients in a sample of 241 with positive depressive symptoms on the
NPI, in contrast with 93 clinically depressed patients in a sample of 264 in the
Borroni study. The key difference is that “depressive symptoms” observed on the
NPI do not necessarily render a diagnosis of depression, and therefore the patients
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in the Borroni sample likely had higher ratings of frequency, severity, and distress
than our patients. Larger numbers of more severely depressed patients may have
made this genetic relationship for depression significant, and apathy is a
characteristic of depression that consequently became statistically significant as
well.
A notable limitation of this study is selection bias: enrolled subjects were
recruited from other research protocols at an academic medical center. Many of
these protocols were investigational drug trials, which may have inadvertently
changed the course of AD progression for our prospective and retrospective
analyses. Most of these experimental treatments were not found to impact the
course of AD, however, and any small effect was likely distributed randomly with
respect to genotype. Ethnically, the patients were overwhelmingly Caucasian.
None of the patients were institutionalized at the time of participation. Further
research should be conducted before results of this study may be elaborated to
other groups. Another significant limitation is reliance upon caregiver interview,
which introduces recall bias both in estimating date of disease onset for
retrospective analyses and in obtaining data for the NPI (78). Nonetheless,
relatives’ prospective and retrospective ratings have been found to be in close
agreement, particularly when the patient still resides in the community (112).
This investigation finds its place in the new era of psychiatric research,
that of the genetics of mental illness. On the road to this understanding, the
complexities of these conditions emerge: a particular gene may be associated
with only a small part of a disease presentation. In the case of this study, the
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effects of a single nucleotide substitution become apparent: the C270T-T allele
contributes to hallucinations and overall neuropsychiatric symptomatology in
patients with AD. A nucleotide substitution in val66met yields a new amino acid,
and that met allele in turn may predict an individual’s ultimate educational
attainment. It is through an aggregate of these individual changes that particular
phenotypes of psychiatric illnesses evolve. “Dementia” is no longer dementia
alone, but dementia with psychosis, dementia with depression, dementia with
agitation; “depression” becomes depression with psychotic features, depression
with anxiety, depression with agitation, and so on.
The clinical applicability of genotyping patients is limited at this stage of
understanding. However, once the genetic basis of psychiatric illness is better
elucidated, it has the potential to revolutionize the way patients are treated. In the
case of patients with the C270T-T allele who develop AD, if it is known that these
patients may be predisposed to develop hallucinations, then caregivers and
physicians may be more in-tune with this psychotic symptom in the patient and
consequently may be able to treat the patient from an early manifestation. This is
true of other neuropsychiatric comorbidities of AD that may be associated with
this allele and others as well. With respect to our finding of lower educational
attainment in met homozygotes, if this finding holds true universally and not just
in a sample of AD patients, then theoretically if children were known to be
genetically disadvantaged to achieve academically, different approaches to
teaching and learning that rely less on rote memorization and more on integrating
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ideas and concepts may help a young student to achieve higher levels of
schooling.
That stated, the concept of genotyping remains controversial in the public
eye. Many at-risk individuals already refuse available genetic tests for heritable
diseases such as Huntington’s disease, colon cancer, and breast cancer, stating
they “don’t want to know” if they are at risk. In the case of AD, neither patients
with mild cognitive impairment nor healthy adults are routinely screened for wellestablished predisposing genetic factors such as the ApoE ε4 allele given that the
genotype does not guarantee development of the disease and therefore is of
limited clinical utility. Some patients worry that discovering a genotype that
predisposes to illness will also impact health insurance coverage, making plans
less available and more costly. However, many individuals are curious to know
their own health risks, and the idea of “personalized medicine” employing
techniques such as genotyping is now becoming a reality.
Although the findings of this study and others may not lead to immediate
genotyping of patients with AD for reasons of practicality, genetic association
studies are helpful in understanding the pathogenesis of the disease. As data is
gathered throughout the field of genetic psychiatry, the molecular basis of
psychiatric diseases is better understood. This understanding begins with the
association, but from there many questions are raised: what about the protein
coded by this gene is influencing the patient’s symptomatology? What makes this
different from the protein coded by this allele in a healthy subject? How is this
different from the protein coded by a different allele in another patient with
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similar symptomatology? How can we use the understanding of these proteins to
develop new therapeutic strategies for our patients? Can new medications be
tailored to genotype? These questions direct the next steps from this
investigation: to examine BDNF genotype in non-AD samples to evaluate if met
homozygotes achieve fewer years of schooling; to determine if non-AD agematched subjects carrying the C270T-T allele are predisposed to increased
neuropsychiatric disturbance; to elucidate what molecularly causes BDNF
expression to decrease in AD, and whether decreased BDNF levels are a cause of
the disease symptomatology or effect of some other pathogenesis; to continue to
examine what other genetic factors may influence the variability of AD
presentation; and to evaluate the role of BDNF as a target for AD therapeutics.

Conclusion
This study demonstrates a relationship of the val66met genotype with
educational attainment in which met homozygotes had significantly fewer years
of education than either val/met or val/val counterparts. No association was
found between cognitive and functional progression and BDNF genotype through
retrospective and prospective analyses. An association between the C270T-T
allele and hallucinations as well as overall NPI score was observed. This is the
first study to exhibit these findings, which should be examined in a more diverse
pool of subjects before generalizing the results. Additionally, more research
should be conducted to understand more clearly the pathological link between
genotype and cognitive, functional, and behavioral outcomes in AD.
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Figure 1
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Fig. 1: Effect of val66met genotype on educational attainment. Met
homozygotes exhibit significantly lower educational attainment than either val/val
or val/met genotypes.
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Table 1. Subject characteristics
All Subjects
(n=341)
Mean SD

Val/Val
(n =203)
Mean SD

Val66Met
Val/Met
(n =117)
Mean SD

Demographics
Age
Sex (% female)
Education (years)

73.8 ± 8.4
62.8%
13.2 ± 3.3

73.3 ± 8.4
63.5%
13.1 ± 3.3

74.4 ± 8.3
58.1%
13.8 ± 3.2

73.9 ± 7.4
83.3%
10.2 ± 2.9b

73.6 ± 8.4
61.1%
13.2 ± 3.4

73.9 ± 8.5
77.4%
13.1 ± 2.5

73.7 ± 8.4
59.6%
13.3 ± 3.4

74.5 ± 8.1
82.1%a
12.8 ± 2.2

Disease Characteristics
Onset age
Duration (years)
Family history (% positive)
ApoE e4 carrier (%)

69.3 ± 8.3
4.5 ± 2.0
48.8%
57.4%

68.8 ± 8.3
4.5 ± 2.0
46.0%
61.4%

70.0 ± 8.2
4.4 ± 2.1
54.7%
52.6%

69.6 ± 8.2
4.3 ± 2.2
41.7%
50.0%

69.17 ± 8.3
4.4 ± 2.0
49.5%
58.3%

69.1 ± 8.2
4.8 ± 1.9
35.4%
50.0%

69.3 ± 8.3
4.4 ± 2.0
51.2%
57.5%

69.9 ± 8.2
4.6 ± 1.5
35.7%
48.1%

Concomitant Therapies at Baseline
Cholinesterase inhibitors (% use)
Antipsychotics (% use)
Antidepressants (% use)
Vitamin E (≥400 IU daily) (% use)

35.2%
3.5%
17.6%
36.1%

38.4%
3.9%
18.2%
34.0%

29.1%
3.4%
14.5%
40.2%

Met/Met
(n =12)
Mean SD

58.3%c
0.0%
41.7%
33.3%

C270T
G-712A
C/C
T-carrier
G/G
A-carrier
(n =301)
(n =31)
(n =282)
(n =28)
Mean SD
Mean SD Mean SD Mean SD

35.5%
3.3%
17.6%
38.2%

32.3%
6.5%
16.1%
19.4%

33.3%
2.8%
16.3%
37.2%

Family history was positive if primary degenerative dementia was present in a first-degree relative.
a

A-carriers were disproportionately female (χ2=4.57, P=.032)

b
c

Met/Met had significantly lower educational attainment than Val/Met (P=.00062) and Val/Val (P=.0068) (ANCOVA; post hoc Tukey test)

Met/Met was significantly more likely than Val/Val or Val/Met to be taking cholinesterase inhibitors (χ2=6.21, P=0.045)

35.7%
7.1%
21.4%
21.4%
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Table 2. Cognitive and functional data at baseline
All Subjects

Val66Met
Val/Met
(n =117)
Mean SD

Met/Met
(n =12)
Mean SD

C270T
C/C
T-carrier
(n =301)
(n =31)
Mean SD
Mean SD

G-712A
G/G
A-carrier
(n =282)
(n =28)
Mean SD
Mean SD

Variable

(n =341)
Mean SD

Val/Val
(n =203)
Mean SD

MMSE (n =341)

17.2 ± 5.5

n = 203
17.3 ± 5.4

n = 117
17.0 ± 5.7

n =12
17.8 ± 5.9

n = 301
17.2 ± 5.5

n =31
17.2 ± 4.7

n =282
17.2 ± 5.6

n =28
17.5 ± 4.5

ADAS-Cog (n =282)

27.1 ± 12.0

n = 167
27.1 ± 12.4

n = 97
27.7 ± 11.5

n =10
24.5 ± 11.2

n =252
27.2 ± 12.1

n =23
27.8 ± 10.4

n =239
27.4 ± 12.1

n =22
27.9 ± 10.8

IADL (n =329)

0.65 ± 0.19

n = 196
0.65 ± 0.19

n = 112
0.65 ± 0.19

n =12
0.65 ± 0.17

n =289
0.65 ± 0.19

n =31
0.68 ± 0.18

n =271
0.65 ± 0.19

n =28
0.68 ± 0.17

ADCS-ADL (n =170)

57.3 ± 14.4

n = 100
57.8 ± 13.4

n = 58
56.0 ± 16.6

n =7
62.0 ± 6.7

n =149
57.3 ± 14.3

n =16
57.0 ± 12.7

n =141
57.4 ± 14.6

n =13
59.5 ± 10.7

Data displayed are baseline cognitive and functional measures adjusted for disease duration, patient age, sex, and education. MMSE =
Mini-Mental State Examination; ADAS-Cog = Alzheimer's Disease Assessment Scale–Cognitive Subscale; IADL = Instrumental Ac

Table 3. Prospective analysis of cognitive and functional data
All Subjects

Variable

(n =341)
Mean SD

Val/Val
(n =203)
Mean SD

Val66Met
Val/Met
(n =117)
Mean SD

Met/Met
(n =12)
Mean SD

C270T
C/C
T-carrier
(n =301)
(n =31)
Mean SD
Mean SD

G/G
(n =282)
Mean SD

A-carrier
(n =28)
Mean SD

MMSE annual change
Number of observations
Duration of observation (yrs)

n =220
-3.12 ± 3.70
6.8 ± 3.5
1.79 ± 1.31

n = 135
-3.17 ± 3.93
6.7 ± 3.1
1.73 ± 1.246

n =73
-3.03 ± 3.51
6.9 ± 4.1
1.87 ± 1.45

n =7
-3.34 ± 1.60
6.4 ± 2.7
1.51 ± 0.65

n =197
-3.11 ± 3.73
6.9 ± 3.5
1.82 ± 1.34

n = 184
-3.04 ± 3.83
7.0 ± 3.6
1.84 ± 1.36

n =14
-4.19 ± 3.98
4.7 ± 2.2
1.14 ± 0.75

ADAS-Cog annual change*
Number of observations
Duration of observation (yrs)

n =184
5.93 ± 9.03
9.4 ± 5.1
1.63 ± 1.22

n = 107
6.13 ± 10.34
8.9 ± 5.0
1.51 ± 1.23

n =66
5.83 ± 7.18
10.1 ± 5.3
1.78 ± 1.24

n =6
5.70 ± 3.77
9.7 ± 4.4
1.61 ± 0.63

n =165
5.63 ± 8.87
9.3 ± 5.0
1.63 ± 1.22

ADCS-ADL annual change
Number of observations
Duration of observation (yrs)

n =160
-10.37 ± 11.17
7.1 ± 3.2
1.39 ± 1.01

n = 97
n =53
-10.10 ± 10.84 -10.34 ± 11.63
6.7 ± 2.7
7.8 ± 4.0
1.30 ± 0.89
1.57 ± 1.23

n =6
n =143
-14.12 ± 13.03 -10.68 ± 11.51
6.7 ± 2.1
7.1 ± 3.3
1.16 ± 0.43
1.40 ± 1.04

Data displayed are longitudinal rates of change per year computed by linear regression.
*Rates of ADAS-Cog change are positive because lower scores indicate better performance.
MMSE = Mini-Mental State Examination; ADAS-Cog = Alzheimer's Disease Assessment Scale–Cognitive Subscale;
ADCS-ADL = Alzheimer's Disease Cooperative Study–Activities of Daily Living.

n =16
-3.93 ± 3.83
5.3 ± 2.9
1.32 ± 1.02
n =14
9.53 ± 11.18
10.4 ± 7.2
1.55 ± 1.27
n =11
-9.55 ± 8.49
5.7 ± 1.7
0.90 ± 0.41

G-712A

n = 157
5.52 ± 8.97
9.5 ± 5.0
1.66 ± 1.25
n = 135
-10.34 ± 11.59
7.2 ± 3.4
1.43 ± 1.07

n =14
9.81 ± 11.27
9.2 ± 5.8
1.36 ± 1.07
n =10
-12.41 ± 10.02
5.9 ± 1.4
0.90 ± 0.34
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Table 4. Analysis of neuropsychiatric symptoms
Frequency
NPI Subscore

(n =248)
%
n

Delusions
Hallucinations
Aggression
Anxiety
Depression
Elation
Apathy
Disinhibition
Irritability
Aberrant Motor Behavior
Sleep Disturbances
Eating Disturbances

76
39
83
73
83
18
95
53
80
96
54
50

a

30.6
15.7
33.5
29.4
33.5
7.3
38.3
21.4
32.3
38.7
21.8
20.2

Val66Met
(n =241)
OR [95% CI]a

C270T
(n =241)
OR [95% CI]b

G712A
(n =222)
OR [95% CI]b

0.64 [0.38-1.09]
0.73 [0.38-1.40]
0.68 [0.41-1.13]
0.95 [0.58-1.55]
0.83 [0.51-1.33]
*
0.82 [0.52-1.31]
0.86 [0.49-1.50]
0.94 [0.59-1.51]
0.71 [0.44-1.16]
0.99 [0.57-1.70]
1.42 [0.84-2.42]

1.39 [0.54-3.6]
3.25 [1.22-8.62]c
2.48 [0.97-6.33]
1.70 [0.68-4.24]
1.47 [0.60-3.64]
*
1.68 [0.69-4.12]
1.73 [0.66-4.58]
1.12 [0.44-2.83]
1.51 [0.61-3.78]
1.20 [0.43-3.31]
0.57 [0.16-2.02]

1.44 [0.53-3.91]
2.76 [0.98-7.78]
1.89 [0.70-5.14]
1.15 [0.41-3.22]
1.99 [0.78-5.10]
*
1.55 [0.59-4.02]
1.43 [0.47-4.33]
1.41 [0.53-3.72]
1.04 [0.39-2.78]
0.96 [0.30-3.11]
0.48 [0.10-2.19]

Odds Ratios for val66met are for the effect of Met-allele dose (2,1,0).
Odds Ratios for for C270T and A712G are for carrier status of the less common allele (C270T-T, A712G-A).
c
Genotype significantly increases risk for symptom, p<.05.
*No carriers of less common allele exhibited Elation.
b
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